Acadia Pharmaceuticals Logo
US0042251084
603035
ACAD

Acadia Pharmaceuticals

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 27,31 € (+66,73%). La mediana è 29,99 € (+83,09%).

Acquista
  25
Mantieni
  11
Vendi
  1

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Acadia Pharmaceuticals: US court preliminarily approves settlement in shareholder derivative suit

    A US district court in California gave preliminary approval to the settlement in the shareholder derivative suit Kanner et al. v. Biggar et al. on August 24, 2026. Acadia must publish the court documents notifying shareholders of the settlement; details are available in the exhibits to the SEC filing. Acadia’s operations remain stable, the stock is trading at $27.83, and analyst ratings as well as recent approvals and clinical progress support a positive outlook. » Altro su de.investing.com


  • Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference

    At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimer’s psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » Altro su de.investing.com


  • Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results

    Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phase‑2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » Altro su de.investing.com


  • FDA grants Acadia fast-track status for Alzheimer's drug remlifanserin

    The FDA has granted fast-track status to Acadia’s compound remlifanserin for the treatment of hallucinations and delusions in Alzheimer’s psychosis. Acadia has completed patient recruitment for the Phase 2 portion of the RADIANT program and expects topline results in September–October 2026; Phase 3 screening and recruitment are already underway. Remlifanserin is an inverse agonist at the 5-HT2A receptor intended to avoid direct dopamine blockade and related safety issues. » Altro su de.investing.com


  • Acadia Pharmaceuticals insider sells nearly half of direct holdings

    James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, sold 11,421 shares in an open-market transaction on June 26, 2026—about 46.6% of his direct holdings—at a weighted average price of $26.08, leaving him with 13,088 shares. The sale, executed under a pre-established Rule 10b5-1 plan, was his largest single open-market disposition and coincided with a share rally after an EMA recommendation for Daybue. Company fundamentals remain strong, with Q1 2026 revenue of $268.1 million and ongoing late-stage pipeline programs. The filings show no derivative or indirect holdings were involved, and recent larger sales reflect reduced available capacity rather than disclosed discretionary changes in strategy. » Altro su finance.yahoo.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Acadia Pharmaceuticals ha registrato ricavi pari a 302,19 Mln € e un utile netto di 47,25 Mln €
(EUR) settembre 2026
YoY
Ricavi 302,19 Mln 27,28%
Utile lordo 271,21 Mln 23,85%
Utile netto 47,25 Mln 22,74%
EBITDA 71,02 Mln 75,28%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
2,94 Mld €
Numero di azioni
172,83 Mln
Massimo/minimo a 52 settimane
28,13 € - 14,41 €
Dividendi No
Beta
0,89
Rapporto P/E
8,80
Rapporto PEG
0,24
Rapporto P/B
2,33
Rapporto P/S
2,70

Profilo aziendale

ACADIA Pharmaceuticals Inc., una società biofarmaceutica, si concentra sullo sviluppo e sulla commercializzazione di farmaci a piccola molecola che rispondono a bisogni medici non soddisfatti nei disturbi del sistema nervoso centrale. L'azienda offre NUPLAZID (pimavanserin) per il trattamento di allucinazioni e deliri associati alla psicosi della malattia di Parkinson. Il suo portafoglio di sviluppo include pimavanserin, in fase di sviluppo di Fase 3 per il trattamento della psicosi associata alla malattia di Alzheimer e dei sintomi negativi della schizofrenia; Trofinetide, un nuovo analogo sintetico, in fase di sviluppo di Fase 3 per il trattamento della sindrome di Rett; ACP-044, un analgesico non oppioide innovativo di prima classe somministrato per via orale, in fase di sviluppo di Fase 2 per il trattamento del dolore acuto e cronico; e ACP-319, un modulatore allosterico positivo del recettore muscarinico, in fase di sviluppo di Fase 1 per il trattamento della schizofrenia e della cognizione nell'Alzheimer. ACADIA Pharmaceuticals Inc. è stata fondata nel 1993 e ha sede a San Diego, California.

Nome
Acadia Pharmaceuticals
CEO
Catherine E. Owen Adams
Sede centrale San Diego, ca
Stati Uniti
Sito web
Settore
Materiali
Industria
Prodotti chimici
Quotazione in borsa
27/05/2004
Dipendenti 797

Simboli di borsa

Borsa Simbolo
NASDAQ
ACAD
Frankfurt
DR6.F
Düsseldorf
DR6.DU
London
0A4W.L
SIX
DR6.SW
München
DR6.MU
🍪

Parqet  usa i cookie. Scopri di più